InvestSMART

Telix Pharmaceuticals Limited (ASX: TLX) - Announcements

- Current share price for TLX : $17.020

ASX company news and announcements for Telix Pharmaceuticals Limited (TLX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Telix Pharmaceuticals Limited (TLX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Telix Pharmaceuticals Limited (TLX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Telix Pharmaceuticals Limited (TLX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$5,776 Q1 2026 Strong Revenue Growth and Tx Pipeline Advancement 7 Apr 2026 8:28AM $12.950 $17.020 risen by 31.43%
$5,776 Ceasing to be a substantial holder 2 Apr 2026 4:18PM $12.950 $17.020 risen by 31.43%
$5,776 Telix Appoints David Gill as Non-Executive Director 2 Apr 2026 9:52AM $13.200 $17.020 risen by 28.94%
$5,776 Change in substantial holding 20 Mar 2026 3:15PM $12.870 $17.020 risen by 32.25%
$5,776 Notification regarding unquoted securities - TLX 20 Mar 2026 8:23AM $12.410 $17.020 risen by 37.15%
$5,776 Appendix 3Y Change in Director Interests - C Behrenbruch 18 Mar 2026 8:24AM $11.700 $17.020 risen by 45.47%
$5,776 Notification of cessation of securities - TLX 18 Mar 2026 8:24AM $11.700 $17.020 risen by 45.47%
$5,776 Becoming a substantial holder 17 Mar 2026 5:32PM $11.700 $17.020 risen by 45.47%
$5,776 Telix Resubmits NDA to FDA for Pixclara Brain Cancer Imaging 16 Mar 2026 8:19AM $11.290 $17.020 risen by 50.75%
$5,776 Becoming a substantial holder from CGF 12 Mar 2026 4:23PM $11.230 $17.020 risen by 51.56%
$5,776 Notification of cessation of securities - TLX 12 Mar 2026 8:30AM $10.760 $17.020 risen by 58.18%
$5,776 Application for quotation of securities - TLX 12 Mar 2026 8:30AM $10.760 $17.020 risen by 58.18%
$5,776 ProstACT Global Phase 3 (Part 1) Results Presentation 10 Mar 2026 8:24AM $10.200 $17.020 risen by 66.86%
$5,776 ProstACT Global Phase 3 (Part 1) Achieves Primary Objectives 10 Mar 2026 8:24AM $10.200 $17.020 risen by 66.86%
$5,776 Pending Release of Shares from Voluntary Escrow 9 Mar 2026 8:19AM $10.750 $17.020 risen by 58.33%
$5,776 Change in substantial holding 6 Mar 2026 7:30PM $10.750 $17.020 risen by 58.33%
$5,776 Application for quotation of securities - TLX 5 Mar 2026 8:56AM $9.470 $17.020 risen by 79.73%
$5,776 Appendix 4G and 2025 Corporate Governance Statement 20 Feb 2026 8:54AM $9.130 $17.020 risen by 86.42%
$5,776 2025 Full Year Results Presentation 20 Feb 2026 8:53AM $9.130 $17.020 risen by 86.42%
$5,776 2025 Full Year Results Announcement 20 Feb 2026 8:53AM $9.130 $17.020 risen by 86.42%
$5,776 Appendix 4E and 2025 Annual Report 20 Feb 2026 8:52AM $9.130 $17.020 risen by 86.42%
$5,776 Change in substantial holding 20 Feb 2026 8:18AM $9.130 $17.020 risen by 86.42%
$5,776 Telix Submits EU MAA for TLX101-Px Brain Cancer Imaging 18 Feb 2026 8:16AM $8.840 $17.020 risen by 92.53%
$5,776 Change in substantial holding 9 Feb 2026 8:11AM $9.850 $17.020 risen by 72.79%
$5,776 App 3Z Final Director Interests - T Olson 4 Feb 2026 8:27AM $10.210 $17.020 risen by 66.70%

51 - 75 of 940 results

Page 3 of 38

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.